Home
Resources
Publications
Pharmacotherapy of Borderline Personality Disorder: Replacing Confusion With Prudent Pragmatism

Pharmacotherapy of Borderline Personality Disorder: Replacing Confusion With Prudent Pragmatism

Vladan Starcevic, Aleksandar Janca

Curr Opin Psychiatry. 2018 Jan;31(1):69-73.

PMID: 29028643

Abstract:

Purpose of review:
The article aims to examine trends in the pharmacological treatment of borderline personality disorder (BPD) and shed more light on the attendant controversies.
Recent findings:
Although specialized, BPD-centred psychotherapy is considered first-line treatment for BPD and no psychotropic drug has been licensed for BPD, medications are frequently prescribed in the management of this condition. Various classes of psychopharmacological agents are used for BPD and there is a prominent polypharmacy. Use of antidepressants for BPD has been decreasing somewhat and use of mood stabilizers and second-generation antipsychotics has been increasing. Although there is a general agreement that little evidence of efficacy of medications exists for BPD, clinicians are either advised to almost completely avoid pharmacotherapy for BPD or use a 'targeted' approach, administering specific medications for the specific symptoms of BPD. This has created some confusion in clinical practice and contributed to a variety of prescribing practices for BPD.
Summary:
Well designed studies of the efficacy of pharmacological agents in BPD are needed. Clinicians should use medications for BPD with caution, usually short term and mainly for symptom relief. They should frequently review a need for ongoing pharmacotherapy and make every effort to avoid polypharmacy.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP213481120	BPD		213481-12-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: